Overview

Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease

Status:
Not yet recruiting

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients. The study was approved by the ethical committee of the Egyptian Center for Research and Regenerative Medicine in 11-5-2020.

Phase:

Phase 2

Details

Lead Sponsor:

National Research Center, Egypt
National Research Centre, Egypt

Collaborator:

Egyptian Military Medical Services

Treatments:

Lactoferrin